Skip to main content

Table 3 Univariate logistic regression analysis of risk factors for mortality

From: Incidence, clinical characteristics, and outcomes of nosocomial Enterococcus spp. bloodstream infections in a tertiary-care hospital in Beijing, China: a four-year retrospective study

Variable

7-day mortality

30-day mortality

 

Survivors

(n = 201)

Non-survivors

(n = 25)

OR (95% CI)

p-value

Survivors

(n = 172)

Non-survivors

(n = 54)

OR (95% CI)

p-value

Age, ≥ 70 years

77 (38, 32–45)

13 (52, 31–71)

1.7 (0.8–4.0)

0.191

65 (38, 30–45)

25 (46, 33–60)

1.4 (0.8–2.6)

0.266

Male gender

130 (65, 58–71)

12 (48, 27–69)

0.5 (0.2–1.2)

0.108

113 (66, 59–73)

29 (54, 40–67)

0.6 (0.3–1.1)

0.113

BMI

   

0.181

   

0.118

 Normal

121 (60, 53–67)

11 (44, 23–65)

1.0

 

104 (60, 53–68)

28 (52, 38–66)

1.0

 

 Malnutrition

19 (9, 5–14)

6 (24, 6–42)

3.5 (1.2–10.5)

0.027

14 (8, 4–12)

11 (20, 9–31)

2.9 (1.2–7.1)

0.019

 Overweight

53 (26, 20–33)

7 (28, 9–47)

1.5 (0.5–4.0)

0.465

47 (27, 21–34)

13 (24, 12–36)

1.0 (0.5–2.2)

0.943

 Obese

8 (4, 1–7)

1 (4, 0–12)

1.4 (0.2–12.0)

0.773

7 (4, 1–7)

2 (4, 0–9)

1.1 (0.2–5.4)

0.943

Comorbidities

 Malignancy

118 (59, 52–66)

12 (48, 27–69)

0.7 (0.3–1.5)

0.310

99 (58, 50–65)

31 (57, 44–71)

1.0 (0.5–1.8)

0.984

 Cardiovascular disease

99 (49, 42–56)

14 (56, 35–77)

1.3 (0.6–3.0)

0.526

85 (49, 42–57)

28 (52, 38–66)

1.1 (0.6–2.0)

0.755

 Pneumonia

58 (29, 23–35)

16 (64, 44–84)

4.4 (1.8–10.5)

0.001 a

47 (27, 21–34)

27 (50, 36–64)

2.7 (1.4–5.0)

0.002 b

 Diabetes mellitus

58 (29, 23–35)

10 (40, 19–61)

1.6 (0.7–3.9)

0.255

46 (27, 20–33)

22 (41, 27–54)

1.9 (1.0–3.6)

0.052b

 Impaired liver function

43 (21, 16–27)

9 (36, 16–56)

2.1 (0.9–5.0)

0.107

36 (21, 15–27)

16 (30, 17–42)

1.6 (0.8–3.2)

0.187

 Cerebrovascular disease

37 (18, 13–24)

4 (16, 1–31)

0.8 (0.3–2.6)

0.768

31 (18, 12–24)

10 (19, 8–29)

1.0 (0.5–2.3)

0.934

 Impaired renal function

22 (11, 7–15)

8 (32, 12–52)

3.8 (1.5–9.9)

0.006 a

14 (8, 4–12)

16 (30, 17–42)

4.8 (2.1–10.6)

0.000 b

 Hemiplegia

25 (12, 8–17)

2 (8, 0–19)

0.6 (0.1–2.8)

0.523

22 (13, 8–18)

5 (9, 1–17)

0.7 (0.3–1.9)

0.487

 Neutropenia

12 (6, 3–9)

2 (8, 0–19)

1.4 (0.3–6.5)

0.692

8 (5, 1–8)

6 (11, 2–20)

2.6 (0.9–7.8)

0.095b

CCI

3 (2–5)

4 (3–6)

1.2 (1.0–1.4)

0.028 a

3 (2–5)

4 (3–6.25)

1.3 (1.1–1.4)

<0.001 b

APACHE II score

7 (5–10)

14 (12–17)

1.2 (1.1–1.3)

<0.001 a

6 (5–8.75)

13 (10–17)

1.3 (1.2–1.4)

<0.001 b

ICU residence

53 (26, 20–33)

13 (52, 31–73)

3.0 (1.3–7.0)

0.010 a

42 (24, 18–31)

24 (44, 31–58)

2.5 (1.3–4.7)

0.005 b

Previous treatment

 Antibiotic exposure

185 (92, 88–96)

25 (100)

 

0.998

156 (91, 86–95)

54 (100)

 

0.998

 Total parenteral nutrition

74 (37, 30–44)

10 (40, 19–61)

1.1 (0.5–2.7)

0.756

58 (34, 27–41)

26 (48, 34–62)

1.8 (1.0–3.4)

0.057b

 Mechanical ventilation

77 (38, 32–45)

10 (40, 19–61)

1.1 (0.5–2.5)

0.870

66 (38, 31–46)

21 (39, 25–52)

1.0 (0.6–1.9)

0.946

 Surgery

69 (34, 28–41)

5 (20, 3–37)

0.5 (0.2–1.3)

0.157

63 (37, 29–44)

11 (20, 9–31)

0.4 (0.2–0.9)

0.029 b

 Chemotherapeutic agent

27 (13, 9–18)

2 (8, 0–19)

0.6 (0.1–2.5)

0.449

24 (14, 9–19)

5 (9, 1–17)

0.6 (0.2–1.7)

0.372

 Immunosuppressive agent

13 (6, 3–10)

5 (20, 3–37)

3.6 (1.2–11.2)

0.026 a

9 (5, 2–9)

9 (17, 6–27)

3.6 (1.4–9.7)

0.010 b

 Renal replacement therapy

11 (5, 2–9)

4 (16, 1–31)

3.3 (1.0–11.3)

0.058a

8 (5, 1–8)

7 (13, 4–22)

3.1 (1.1–8.9)

0.040 b

 Invasive devices

  Central intravenous catheter

86 (43, 36–50)

16 (64, 44–84)

2.4 (1.0–5.6)

0.049 a

71 (41, 34–49)

31 (57, 44–71)

1.9 (1.0–3.6)

0.039 b

  Dwell time of central intravenous catheter

15 (7, 26)

14 (7, 24)

1.0 (1.0–1.0)

0.919

15 (7.5, 26.75)

14 (6.5, 23.25)

1.0 (1.0–1.0)

0.465

  Indwelling urinary catheter

90 (45, 38–52)

14 (56, 35–77)

1.6 (0.7–3.6)

0.291

76 (44, 37–52)

28 (52, 38–66)

1.4 (0.7–2.5)

0.325

  Endotracheal intubation

76 (38, 31–45)

10 (40, 19–61)

1.1 (0.5–2.6)

0.832

65 (38, 30–45)

21 (39, 25–52)

1.1 (0.6–2.0)

0.885

  Peripheral intravenous catheter

62 (31, 24–37)

7 (28, 9–47)

0.9 (0.4–2.2)

0.771

53 (31, 24–38)

16 (30, 17–42)

1.0 (0.5–1.8)

0.869

  Tracheostomy tube

19 (9, 5–14)

1 (4, 0–12)

0.4 (0.1–3.1)

0.381

16 (9, 5–14)

4 (7, 0–15)

0.8 (0.3–2.4)

0.670

Enterococcal species

   

0.772

   

0.175

E. faecium

146 (73, 66–79)

21 (84, 69–99)

1.0

 

122 (71, 64–78)

45 (83, 73–94)

1.0

 

E. faecalis

42 (20, 15–26)

4 (16, 1–31)

0.7 (0.2–2.0)

0.472

38 (22, 16–28)

8 (15, 5–25)

0.6 (0.3–1.3)

0.188

 Others

13 (6, 3–10)

0 (0)

0.0

0.999

12 (7, 3–11)

1 (2, 0–6)

0.2 (0.0–1.8)

0.159

Source of BSIs

 Abdominal

83 (41, 34–48)

9 (36, 16–56)

0.8 (0.3–1.9)

0.612

72 (42, 34–49)

20 (37, 24–50)

0.8 (0.4–1.5)

0.529

 Unknown

56 (28, 22–34)

9 (36, 16–56)

1.5 (0.6–3.5)

0.399

47 (27, 20–33)

18 (33, 20–46)

1.3 (0.7–2.6)

0.396

 Central venous catheter

37 (18, 13–24)

4 (16, 1–31)

0.8 (0.3–2.6)

0.768

33 (19, 13–25)

8 (15, 5–25)

0.7 (0.3–1.7)

0.468

 Genitourinary

12 (6, 3–9)

2 (8, 0–19)

1.4 (0.3–6.5)

0.692

9 (5, 2–9)

5 (9, 1–17)

1.9 (0.6–5.8)

0.281

 Pneumonia

7 (3, 1–6)

1 (4, 0–12)

1.2 (0.1–9.8)

0.895

7 (4, 1–7)

1 (2, 2–6)

0.5 (0.1–3.7)

0.453

Polymicrobial infection

18 (9, 5–13)

3 (12, 0–26)

1.4 (0.4–5.1)

0.622

14 (8, 4–12)

7 (13, 4–22)

1.7 (0.6–4.4)

0.291

Vancomycin-resistant

7 (3, 1–6)

0 (0)

0.0

0.999

5 (3, 0–5)

2 (4, 0–9)

1.3 (0.2–6.8)

0.769

Appropriate emperical antimicrobial treatment

200 (100, 99–100)

13 (52, 31–73)

0.0 (0.0–0.1)

<0.001 a

172 (100)

41 (76, 64–88)

0.2 (0.1–0.5)

<0.001 b

  1. Data are presented as n (%,95% CI) or median (IQR)
  2. Significant variables are appeared in bold and italics text
  3. aVariables entered into multivariable logistic regression model of risks factors for 7-day mortality
  4. bVariables entered into multivariable logistic regression model of risks factors for 30-day mortality